Astellas- Drug ASP546C for CLDN18.2-expressing solid tumors (546C-CL-0201) - Clinical Trial
Who Can Participate in the Study?
Age Group
Adults
Study Details
Full Title
[546C-CL-0201] A Phase 1b/2 Open-label Study to Assess the Safety and Efficacy of ASP546C in Participants with CLDN18.2-expressing Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma, Pancreatic Adenocarcinoma or Other Solid Tumor Types
Principal Investigator
John H. Strickler, MD
Medical Oncologist
Protocol Number
IRB:
PRO00119707
NCT:
NCT07488676
Phase
Phase I/II
ClinicalTrials.gov
View on ClinicalTrials.gov
Enrollment Status
Open for Enrollment